emirates7 - AstraZeneca has unveiled plans to invest US$50 billion in the United States by 2030, reinforcing the country's position as a global leader in pharmaceutical manufacturing and research and development (R&D).
This major investment is expected to generate tens of thousands of new high-skilled jobs, both directly and indirectly, driving economic growth and supporting the development of advanced therapies for patients in the U.S. and around the world.
At the heart of this initiative is the construction of a cutting-edge, multi-billion-dollar manufacturing facility in Virginia, which will become the company’s largest single investment in manufacturing to date. The plant will focus on producing drug substances for AstraZeneca’s innovative weight management and metabolic treatments, including oral GLP-1 therapies, baxdrostat, oral PCSK9, and combination small molecule drugs. It will manufacture small molecules, peptides, and oligonucleotides, and will employ artificial intelligence, automation, and advanced data analytics to enhance production efficiency.
This multi-billion-dollar project adds to the US$3.5 billion investment announced in November 2024.
In addition to the Virginia site, the broader US$50 billion plan over the next five years includes expanding the R&D hub in Gaithersburg, Maryland; constructing a world-class research centre in Kendall Square, Cambridge, Massachusetts; establishing cell therapy manufacturing facilities in Rockville, Maryland and Tarzana, California; continuing production expansion in Mount Vernon, Indiana; and enlarging specialty manufacturing operations in Coppell, Texas.
This major investment is expected to generate tens of thousands of new high-skilled jobs, both directly and indirectly, driving economic growth and supporting the development of advanced therapies for patients in the U.S. and around the world.
At the heart of this initiative is the construction of a cutting-edge, multi-billion-dollar manufacturing facility in Virginia, which will become the company’s largest single investment in manufacturing to date. The plant will focus on producing drug substances for AstraZeneca’s innovative weight management and metabolic treatments, including oral GLP-1 therapies, baxdrostat, oral PCSK9, and combination small molecule drugs. It will manufacture small molecules, peptides, and oligonucleotides, and will employ artificial intelligence, automation, and advanced data analytics to enhance production efficiency.
This multi-billion-dollar project adds to the US$3.5 billion investment announced in November 2024.
In addition to the Virginia site, the broader US$50 billion plan over the next five years includes expanding the R&D hub in Gaithersburg, Maryland; constructing a world-class research centre in Kendall Square, Cambridge, Massachusetts; establishing cell therapy manufacturing facilities in Rockville, Maryland and Tarzana, California; continuing production expansion in Mount Vernon, Indiana; and enlarging specialty manufacturing operations in Coppell, Texas.